Exicure Inc. (XCUR)
11.58
0.28 (2.48%)
At close: Apr 11, 2025, 3:49 PM
11.26
-2.75%
After-hours: Apr 11, 2025, 05:44 PM EDT
Company Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology.
Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.
The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure Inc.
| Country | United States |
| IPO Date | May 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Andy Yoo |
Contact Details
Address: 2430 North Halsted Street Chicago, Illinois United States | |
| Website | https://www.exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M2008 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andy Yoo | Chief Executive Officer, President & Director |
| Seung Ik Baik | Chief Financial Officer, Secretary & Director |
| Joshua Miller | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 26, 2025 | 4 | Filing |
| Mar 24, 2025 | 3 | Filing |
| Mar 24, 2025 | 3 | Filing |
| Mar 24, 2025 | 3 | Filing |
| Mar 24, 2025 | 3 | Filing |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 4 | Filing |